| Gene symbol | BCL2 | Synonyms | Bcl-2, PPP1R50 | Type of gene | protein-coding |
| Chromosome | 18 | Map location | 18q21.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | BCL2 apoptosis regulator | ||||
| GTO ID | GTC1205 |
| Trial ID | NCT00059813 |
| Disease | Renal Cell Cancer |
| Altered gene | Bcl-2 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | Genasense|G3139|oblimersen sodium |
| Co-treatment | recombinant interferon alfa |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A Phase II Trial of G3139 (Genasense) Anti-Bcl-2 Antisense Oligonucleotide Plus Alpha-Interferon in Metastatic Renal Cancer |
| Year | 2003 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | NCI-2012-02828|NCI-2012-02828|PHII-42|5828|N01CM17101 |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||